These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9339268)

  • 61. A novel derivative of xanomeline improved memory function in aged mice.
    Cui YH; Si W; Yin L; An SM; Jin J; Deng SN; Cao XH
    Neurosci Bull; 2008 Aug; 24(4):251-7. PubMed ID: 18668154
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
    Cutler NR; Sramek JJ
    Eur J Clin Pharmacol; 1995; 48(6):421-8. PubMed ID: 8582458
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
    Paul SM; Yohn SE; Brannan SK; Neugebauer NM; Breier A
    Biol Psychiatry; 2024 Oct; 96(8):627-637. PubMed ID: 38537670
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease.
    Tractenberg RE; Gamst A; Thomas RG; Patterson M; Schneider LS; Thal LJ
    J Neuropsychiatry Clin Neurosci; 2002; 14(3):303-10. PubMed ID: 12154155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High-performance liquid chromatographic assay for xanomeline, a specific M-1 agonist, and its metabolite in human plasma.
    Kasper SC; Bonate PL; DeLong AF
    J Chromatogr B Biomed Appl; 1995 Jul; 669(2):397-403. PubMed ID: 7581918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacological approaches to targeting muscarinic acetylcholine receptors.
    Matera C; Tata AM
    Recent Pat CNS Drug Discov; 2014; 9(2):85-100. PubMed ID: 25413004
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer's disease.
    Hori K; Konishi K; Watanabe K; Uchida H; Tsuboi T; Moriyasu M; Tominaga I; Hachisu M
    Neuropsychobiology; 2011; 63(3):147-53. PubMed ID: 21228606
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management of problematic behavioral symptoms associated with dementia: a cognitive developmental approach.
    Matteson MA; Linton AD; Cleary BL; Barnes SJ; Lichtenstein MJ
    Aging (Milano); 1997 Oct; 9(5):342-55. PubMed ID: 9458995
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000.
    Lopez OL; Becker JT; Sweet RA; Klunk W; Kaufer DI; Saxton J; DeKosky ST
    J Neuropsychiatry Clin Neurosci; 2003; 15(1):67-73. PubMed ID: 12556574
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change.
    Homma A; Nakamura Y; Kobune S; Haraguchi H; Kodani N; Takami I; Matsuoka J; Matsuda H; Kusunoki T
    Dement Geriatr Cogn Disord; 2006; 21(2):97-103. PubMed ID: 16352896
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.
    Greenlee W; Clader J; Asberom T; McCombie S; Ford J; Guzik H; Kozlowski J; Li S; Liu C; Lowe D; Vice S; Zhao H; Zhou G; Billard W; Binch H; Crosby R; Duffy R; Lachowicz J; Coffin V; Watkins R; Ruperto V; Strader C; Taylor L; Cox K
    Farmaco; 2001 Apr; 56(4):247-50. PubMed ID: 11421251
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Psychiatric symptoms associated with Alzheimer's disease.
    Mendez MF; Martin RJ; Smyth KA; Whitehouse PJ
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):28-33. PubMed ID: 2136060
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A treatment and withdrawal trial of besipirdine in Alzheimer disease.
    Huff FJ; Antuono PG; Delagandara JE; McDonald MA; Cutler NR; Cohen SR; Green RC; Zemlan FP; Crismon ML; Alter M; Shipley JE; Reichman WE
    Alzheimer Dis Assoc Disord; 1996; 10(2):93-102. PubMed ID: 8727171
    [TBL] [Abstract][Full Text] [Related]  

  • 74. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.
    Hollander E; Davidson M; Mohs RC; Horvath TB; Davis BM; Zemishlany Z; Davis KL
    Biol Psychiatry; 1987 Sep; 22(9):1067-78. PubMed ID: 3651528
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
    Sauder C; Allen LA; Baker E; Miller AC; Paul SM; Brannan SK
    Transl Psychiatry; 2022 Nov; 12(1):491. PubMed ID: 36414626
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Alzheimer dementia: Starting, stopping drug therapy.
    Kim LD; Factora RM
    Cleve Clin J Med; 2018 Mar; 85(3):209-214. PubMed ID: 29522388
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment.
    Chung JA; Cummings JL
    Neurol Clin; 2000 Nov; 18(4):829-46. PubMed ID: 11072263
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effectiveness of amiridin in senile dementia of the Alzheimer's type.
    Bukatina EE; Grigor'eva IV; Sokol'chik EI
    Neurosci Behav Physiol; 1993; 23(1):83-9. PubMed ID: 8464548
    [No Abstract]   [Full Text] [Related]  

  • 79. Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia.
    Kidambi N; Elsayed OH; El-Mallakh RS
    Neuropsychiatr Dis Treat; 2023; 19():1145-1151. PubMed ID: 37193547
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and tolerability of CI-979 in patients with Alzheimer's disease.
    Sramek JJ; Sedman AJ; Reece PA; Hourani J; Bockbrader H; Cutler NR
    Life Sci; 1995; 57(5):503-10. PubMed ID: 7623616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.